Director, Global Commercial Strategy, Autoantibody

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at jnj.com.

As guided by Our Credo, Johnson & Johnson is responsible to our employees who work with us throughout the world. We provide an inclusive work environment where each person is considered as an individual. At Johnson & Johnson, we respect the diversity and dignity of our employees and recognize their merit.

Job Function:

Marketing

Job Sub Function:

Strategic Marketing

Job Category:

People Leader

All Job Posting Locations:

Horsham, Pennsylvania, United States of America

Job Description:

Johnson & Johnson Innovative Medicine is currently recruiting for a Director, Global Commercial Strategy, Autoantibody, to be located in Horsham, PA.

About Innovative Medicine:
Our expertise in Innovative Medicine is informed and inspired by patients, whose insights fuel our science-based advancements. Visionaries like you work on teams that save lives by developing the medicines of tomorrow.
Join us in developing treatments, finding cures, and pioneering the path from lab to life while championing patients every step of the way.
Learn more at https://www.jnj.com/innovative-medicine 

This is a hybrid role available in Horsham, PA. While specific cities are listed in the Locations section for reference, please note that they are examples only and do not limit your application. We invite candidates from any location to apply.

Purpose: The Director, Global Commercial Strategy, Autoantibody, will contribute to the groundbreaking work that Johnson & Johnson is doing to improve outcomes in patients affected by autoantibody driven diseases. This role has a preferred candidate identified.

This role is accountable for:

• Shaping the clinical programs with deep customer and market insights to optimize the opportunity for the oral FcRn program.
• Providing the prioritized commercial view for opportunities aligned to disease area strategy; crafting asset valuations in partnership with global analytics and delivering clear communication of case through governance process
• Leading the development of target product profiles and provide strategic commercial input into clinical study development, product development decisions, and labeling to improve value creation.
• Partnering with the Nipocalimab and Deep Depletion team to leverage synergies and to deliver aligned commercial indication strategies for the oral FcRn program.

Key responsibilities include but are not limited to:

• Serve as the commercial leader to the Clinical Development Teams (CDTs) for the oral FcRn program
• Inform the clinical programs with rich market insights. Support investment and other decisions with strategic rationale and business case assessments.
• Develop knowledge and insights of health care providers/care market and to identify commercial advantages and anticipate challenges to adoption.
• Partner with Market Access and Med Affairs to ensure a differentiated and integrated TPP, development, and life cycle management plan
• Work with key cross-functional partners (Analytics, Finance, Competitive Intelligence, etc.) to develop differentiating value proposition and commercial forecast valuation models.
• Effectively navigate the J&J network, leverage relationships and credibility to advocate for DAS positions, and influence key stakeholders and decision makers

• Adopting a patient centric view to the treatment of autoantibody today and in the future

At Johnson & Johnson, what matters most is helping people live full and healthy lives. We focus on treating, curing and preventing some of the most devastating and complex diseases of our time. And we pursue the most promising science, wherever it might be found.

That promising science is coming to fruition in autoantibody diseases which includes the oral FcRn and deep depletion portfolio.  Autoantibody diseases occur when antibodies, whic